Improved monitoring of blood glucose for diabetes patients

Eyesense and Capsulution sign development contract
(PresseBox) (Berlin, ) The swiss company Eyesense AG and the Berlin based Capsulution Nanoscience AG have recently signed a development contract aiming at the development of innovative and more user friendly products for diabetes patients to monitor blood sugar levels.

These products for a pain free and more reliable measurement of blood sugar levels are being developed under the direction of Eyesense AG. “The new product eases the procedure for frequent blood glucose level measures and helps diabetes patients to control and maintain healthy blood glucose levels.”, said Dr. Peter Herbrechtsmeier, CEO of Eyesense. Thereby common sequela of diabetes, for example cardiovascular disease or loss of sight, can be reduced.

Both companies count on their long experience in joint developmental work. Capsulution makes a major contribution to the product by taking advantage of its tunable nano-capsules. The biocompatible capsules ensure the measurement of the blood glucose near the human eye. The frequent measurement of the blood sugar concentration is performed by a special portable measuring instrument developed by Eyesense.

About Eyesense AG:
EyeSense AG is a venture-backed diagnostic device company based in Basel and operations close to Frankfurt a. Main, Germany. Eyesense was founded in 2006 as a spin-out from Ciba Vision AG (a Novartis company) and develops ophthalmic diagnostic systems focusing on glucose testing for diabetic patients. In addition to glucose, the testing platform being developed by Eyesense has the potential to measure a broad variety of medical-relevant analytes in patients.


Capsulution Pharma AG
Volmerstr. 7b
D-12489 Berlin
Dipl.-Kfm. Alexander Herrmann
Capsulution NanoScience AG
Chief Financial Officer (CFO)
Dr. Peter Herbrechtsmeier
Chief Executive Officer (CEO)
Social Media